Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene- expression microarray analysis

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1057-1062

  Iwahashi, Shuichi ^a   Shimada, Mitsuo ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Mori, Hiroki ^a   Hanaoka, Jun ^a   Saito, Yu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cholangiocarcinoma; Histone deacetylase inhibitor; Ingenuity pathways analysis; Microarray analysis; Valproic acid

Indexed keywords

GEMCITABINE; HLA DR ANTIGEN; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DRUG SYNERGISM; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICROARRAY ANALYSIS; VALPROIC ACID;

EID: 80053150543     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1407     Document Type: Article

References (32)

1. Cereda S, Passoni P, Reni M, et al: The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer 116: 2208-2214, 2010.
2. Shimada M, Sugimoto K, Iwahashi S, et al: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45: 896-902, 2010.
3. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.
4. Iwahashi S, Ishibashi H, Utsunomiya T, et al: Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest 58: 106-109, 2011.
5. Haberland M, Montgomery RL and Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009.
6. Patra SK, Patra A and Dahiya R: Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287: 705-713, 2001. (Pubitemid 32912772)
7. Lin RJ, Nagy L, Inoue S, et al: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811-814, 1998. (Pubitemid 28099682)
8. Miyake K, Yoshizumi T, Imura S, et al: Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36: e1-e9, 2008. (Pubitemid 351440946)
9. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006. (Pubitemid 43054973)
10. Glozak MA and Seto E: Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007. (Pubitemid 47255924)
11. Göttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001. (Pubitemid 34062289)
12. Jones J, Bentas W, Blaheta RA, et al: Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 22: 293-299, 2008.
13. Xia Q, Sung J, Chowdhury W, et al: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006. (Pubitemid 44197704)
14. Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984, 2003.
15. Rundall BK, Denlinger CE and Jones DR: Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138: 360-367, 2005. (Pubitemid 41253822)
16. Nichole B, Nohea A, Jason G and Murray K: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18-26, 2007.
17. Armstrong TD, Clements VK, Martin BK, Ting JP and Ostrand-Rosenberg S: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94: 6886-6891, 1997. (Pubitemid 27281960)
18. Baskar S, Azarenko V, Garcia Marshall E, Hughes E and Ostrand-Rosenberg S: MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol 155: 123-133, 1994. (Pubitemid 24136476)
19. Ma XC, Hattori T, Kushima R, Terata N and Kodama M: Expression of HLA-class II antigen in gastric carcinomas. Its relationship to histopathological grade, lymphocyte infiltration and five-year survival rate. Acta Oncologica 33: 187-190, 1994. (Pubitemid 24178961)
20. Ishigami S, Aikou T, Natsugoe S, et al: Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 55: 65-69, 1998. (Pubitemid 128707626)
21. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC and Murray AK: An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76: 836-844, 1997. (Pubitemid 27401932)
22. Matoba K, Iizuka N, Gondo T, et al: Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 115: 231-240, 2005. (Pubitemid 40586731)
23. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000. (Pubitemid 30627729)
24. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer 1: 194-202, 2001. (Pubitemid 33741894)
25. Kramer OH, Gottlicher M and Heinzel T: Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12: 294-300, 2001. (Pubitemid 33714220)
26. You JS, Kang JK, Seo DW, et al: Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Res 69: 5716-5725, 2009.
27. Beresford GW and Boss JM: CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nature Immunol 2: 652-657, 2001. (Pubitemid 32677634)
28. Masternak K and Reith W: Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation. EMBO J 21: 1379-1388, 2002. (Pubitemid 34246516)
29. Niesen MI and Blanck G: Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 32: 480-482, 2009.
30. Osborne A, Zhang H, Yang WM, Seto E and Blanck G: Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol 21: 6495-6506, 2001. (Pubitemid 32927417)
31. Warrell RP Jr, He LZ, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998. (Pubitemid 28523436)
32. Blaheta RA, Michaelis M, Driever PH and Cinatl J Jr: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25: 383-397, 20